Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.52 |
| ▸ | F13A1 | P00488 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.50 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461114 | 0.98 | DPP3 (0.55) | DPP3CXCR4F13A1TGM2CTSL | |
| SCHEMBL34461111 | 0.95 | DPP3 (0.56) | DPP3CXCR4F13A1TGM2CTSL | |
| SCHEMBL34461090 | 0.93 | DPP3 (0.59) | DPP3CXCR4CTSLCTSSCTSK | |
| SCHEMBL31001651 | 0.92 | CXCR4 (0.59) | DPP3CXCR4F13A1TGM2CTSL | |
| SCHEMBL30343341 | 0.91 | DPP3 (0.55) | DPP3CXCR4F13A1TGM2CTSL | |
| SCHEMBL34461092 | 0.91 | CXCR4 (0.59) | DPP3CXCR4F13A1TGM2C5AR1 | |
| SCHEMBL34461077 | 0.90 | CXCR4 (0.58) | DPP3CXCR4C5AR1KISS1RIL23R | |
| SCHEMBL34461093 | 0.89 | KISS1R (0.57) | DPP3CXCR4C5AR1KISS1RIL23R | |
| SCHEMBL31001650 | 0.88 | CXCR4 (0.61) | DPP3CXCR4C5AR1IL23R | |
| SCHEMBL34461097 | 0.86 | CXCR4 (0.59) | DPP3CXCR4C5AR1KISS1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | MC1R, MC4R, MC5R | DPP3 359/4885CXCR4 2538/4885F13A1 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.